Papers of the Week

Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the US and EU to treat excessive daytime sleepiness in obstructive sleep apnea (37.5-150 mg/d) and narcolepsy (75-150 mg/d). This analysis evaluated solriamfetol's efficacy in subgroups of participants with OSA who were adherent or nonadherent to primary OSA therapy at baseline and examined whether solriamfetol affected use of primary therapy in an open-label extension trial.